Search
CytomX Therapeutics Inc
CTMXAdd to Watchlist
3.220USD
+0.120+3.87%
Close 07-31 16:00（ET）Quotes delayed by 15 min
548.00MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of CytomX Therapeutics Inc is 8.89, ranking 39 out of 385 in the Biotechnology & Medical Research industry. The average price target is 6.50, with a high of 10.00 and a low of 6.00.
Analyst Rating
Based on
8
analysts
Strong Buy
Current Rating
12.571
Target Price
+305.53%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
CytomX Therapeutics Inc
CTMX
8
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
Kymera Therapeutics Inc
KYMR
24
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is CytomX Therapeutics Inc's expected revenue for the next quarter?
CytomX Therapeutics Inc's expected revenue is 12.31M.
What is CytomX Therapeutics Inc's price target?
Analysts forecast that CytomX Therapeutics Inc's price target is USD 6.50, with the highest forecast at USD 10.00 and the lowest forecast at USD 6.00.
How have CytomX Therapeutics IncCTMX's recent earnings per share performed?
The market expectation was USD -0.10, while CytomX Therapeutics IncCTMX's earnings per share (EPS) for the previous quarter was USD -0.17. EPS for the next quarter is expected at USD -0.08.
What is the analyst rating for CytomX Therapeutics Inc?
Based on the ratings of CytomX Therapeutics Inc's stock from 8 analysts, most analysts support a STRONG BUY trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as STRONG BUY. Please note that this is not trading advice. You still need to conduct your own analysis.